论文部分内容阅读
我院1993年1月～1996年1月用阿克拉霉素(Acl)、三尖杉酯碱(Har)、阿糖胞苷(Ara-C)组成的HAA方案治疗急性非淋巴细胞白血病(ANLL)25例,取得较满意疗效。1 材料和方法1.1 病例选择 25例ANLL均系住院患者,男15例,女10例,年龄14～59岁,中位年龄29岁,按文献标准诊断:M_1 2例,M_2 14例,M_4 1例,M_5 8例。初治20例,复发性2例,难治性3例。1.2 治疗方法 Har 3mg/d,静滴7d;Acl 20mg/d,静滴3d;Ara-C 200mg/d,静滴7d,7d一疗程,间歇10～14d重复下一疗程,3个疗程未能获得完全缓解者换用其它方案治疗。化疗期间给予足够支持治疗,输成分血,有感染时联合应用抗生素。定期复查肝、肾功能,作心电图检查,每周查血象3次,每疗程结束后作骨髓检查。1.3 缓解后治疗 完全缓解后间隔2～3周重复HAA方案巩固2疗程。然后用DAE方案:柔红霉素(D)40mg/d,静滴3d;Ara-C 300mg/d,静滴7d;足叶乙甙(E)100mg/d,静滴5d,与HAA方案交替
In our hospital from January 1993 to January 1996, HALA regimen consisting of Acl, Harrington, and Ara-C was used to treat acute non-lymphocytic leukemia (ANLL) 25 cases achieved satisfactory results. 1 Materials and methods 1.1 Case selection 25 cases of ANLL were hospitalized patients, 15 males and 10 females, aged 14 to 59 years, median age 29 years, according to the literature standard diagnosis: M_1 2 cases, M_2 14 cases, M_4 1 Example, M_5 8 cases. Twenty cases were initially treated, 2 cases were recurrent, and 3 cases were refractory. 1.2 Treatments Har 3mg/d, Intravenous 7d; Acl 20mg/d, Intravenous 3d; Ara-C 200mg/d, Intravenous 7d, 7d One course of treatment, Intermittent 10~14d repeat the next course of treatment, 3 courses fail Get complete remission for treatment with other options. Adequate supportive treatment during chemotherapy, blood transfusion, and antibiotics in combination with infection. Hepatic and renal functions were regularly reviewed for electrocardiogram examinations. Blood samples were taken 3 times a week. Bone marrow tests were performed after each course of treatment. 1.3 Post-Remission Treatment After complete remission, repeat the HAA protocol 2 to 3 weeks to consolidate 2 courses. Then use the DAE protocol: daunorubicin (D) 40 mg/d, intravenous infusion 3 d; Ara-C 300 mg/d, intravenous infusion 7 d; etoposide (E) 100 mg/d, intravenous infusion 5 d, alternating with HAA protocol